. 2017 Sep 12;6(8):580–588. doi: 10.1530/EC-17-0171
This work is licensed under a Table 2.
Description of patients at first diagnosis of hyperprolactinaemia and their comparison cohort.
| Characteristic | Hyperprolactinaemia (n = 1204) | Comparison cohort (n = 5888) | P |
|---|---|---|---|
| n (%) | |||
| Gender- female | 943 (78.3) | 4602 (78.2) | =0.901 |
| SIMD quintile | |||
| 1 most deprived | 309 (26.4) | 1162 (20.5) | |
| 2 | 230 (19.7) | 995 (17.6) | |
| 3 | 184 (15.7) | 926 (16.4) | |
| 4 | 306 (26.2) | 1634 (28.9) | |
| 5 most affluent | 141 (12.1) | 940 (16.3) | <0.001 |
| Diabetes Mellitus | 70 (5.8) | 204 (3.5) | <0.001 |
| Non-fatal Cardiovascular disease | 62 (5.2) | 183 (3.1) | <0.001 |
| Cancer | 101 (8.4) | 411 (6.9) | =0.085 |
| Bone fractures | 76 (6.3) | 264 (4.5) | =0.007 |
| Infectious conditions | 198 (16.5) | 588 (9.9) | <0.001 |
| Renal impairment | 79 (6.5) | 378 (6.4) | =0.855 |
| Medication use | |||
| Bisphosphonate | 16 (1.3) | 62 (1.1) | =0.403 |
| Prednisolone | 93 (7.7) | 282 (4.8) | <0.001 |
| HRT | 205 (17.0) | 1270 (21.6) | <0.001 |
| Mean (s.d.) | |||
| Age (years)* | 39.5 (16.5) | 38.7 (15.6) | =0.123 |
| Serum prolactin (U/L) | 1514 (1177–2382) | 193 (143–255) | <0.001 |
| Serum TSH (U/L) ϕ | 2.2 (1.4–3.9) | 2.4 (1.6–3.5) | =0.003 |
(*) Age at study entry (ϕ) Maximum serum concentration: median (interquartile range).
HRT, Oestrogen containing hormone replacement therapy; SIMD, Scottish Index of Multiple Deprivation; TSH, Thyroid-stimulating hormone.